This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu

Consider IPD protection against what matters1

When it comes to protecting your pediatric patients against IPD, the number of serotypes in a vaccine is just one aspect to consider1,2

Although more than 100 S. pneumoniae serotypes have been documented, only a few of them cause most pediatric pneumococcal infections2

In a pooled analysis from 2019-2023, ~1 in 4 cases of IPD in children younger than 5 years old were caused by serotypes1,a

Serotype 3 (~11%)Serotype 3 (~11%)
Serotype 22F (~9%)
Serotype 33F (~7%)

These 3 key serotypes are associated with higher morbidity and mortality rates in children.3-5,a

Percentage of IPD caused by Serotype 3 in children <5 years of age (1998–2023)6,7

Percentage of IPD Caused by Serotype 3 in Children Less Than 5 Years of Age From 1998 to 2023

Serotype 3 continues to be a leading cause of pediatric IPD despite being included in PCVs for over 15 years1,8

aIn a pooled analysis of national-level CDC ABC surveillance data from 2019–2023, the top 5 IPD-causing serotypes in children under 5 years of age were 19F, 3, 22F, 15C, and 33F. Serotype 15C is not included in any recommended pediatric PCV in the US.1,9,10

ABC, Active Bacterial Core; CDC, Centers for Disease Control and Prevention; IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.

Get details on early disease protection

Get details on early disease protection

See immunogenicity data

See immunogenicity data

Learn about special populations

Learn about special populations

View safety & tolerability data

View safety & tolerability data

References:

  1. Centers for Disease Control and Prevention (CDC). 2019–2023 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance. Updated March 14, 2025. Accessed August 26, 2025. data.cdc.gov/d/qvzb-qs6p/visualization
  2. Gierke R, Wodi P, Kobayashi M. Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book). 14th edition. Chapter 17: Pneumococcal disease. Centers for Disease Control and Prevention. Last reviewed August 2021. Accessed May 16, 2025. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-17-pneumococcal-disease.html
  3. Hu T, Weiss T, Owusu-Edusei K, Petigara T. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States. J Med Econ. 2020;23(12):1653-1660. doi:10.1080/13696998.2020.1840216
  4. Yildirim M, Keskinocak P, Hinderstein S, et al. A comprehensive analysis of serotype-specific invasive capacity, clinical presentations, and mortality trends of invasive pneumococcal disease. Vaccine. 2025;47:126692. doi:10.1016/j.vaccine.2024.126692
  5. Varghese J, Chochua S, Tran T, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2020;26(4):512.e1-512. e10. doi:10.1016/j.cmi.2019.09.008
  6. Centers for Disease Control and Prevention (CDC). 1998–2023 Serotype 3 data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance. Updated March 14, 2025. Accessed March 21, 2025. data.cdc.gov/d/qvzb-qs6p/visualization
  7. Centers for Disease Control and Prevention (CDC). 1998–2023 serotype data for invasive pneumococcal disease cases by age group from Active Bacterial Core surveillance. Updated March 14, 2025. Accessed March 21, 2025. data.cdc.gov/d/qvzb-qs6p/visualization
  8. Prevnar 13. Prescribing Information. Pfizer, Inc.; 2019.
  9. Pneumococcal vaccine recommendations. Centers for Disease Control and Prevention. Last reviewed October 26, 2024. Accessed November 18, 2024. https://www.cdc.gov/pneumococcal/hcp/vaccine-recommendations/index.html
  10. Prevnar 20. Prescribing Information. Pfizer, Inc.; 2023
ExternalSitePopup

By clicking on this link, you will be leaving Merck Vaccines.

Cancel
Proceed
Cancel
Proceed

Indications and Usage

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications and Usage
Select Safety Information

VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) is indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older.

Select Safety Information

Do not administer VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) to individuals with a severe allergic reaction (eg, anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

 

Some individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to VAXNEUVANCE.

 

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Vaccination of premature infants should be based on the infant’s medical status and the potential benefits and possible risks.

 

The most commonly reported solicited adverse reactions in children vaccinated at 2, 4, 6, and 12 through 15 months of age, provided as a range across the 4-dose series, were: irritability (57.3% to 63.4%), somnolence (24.2% to 47.5%), injection-site pain (25.9% to 40.3%), fever ≥38.0°C (13.3% to 20.4%), decreased appetite (14.1% to 19.0%), injection-site induration (13.2% to 15.4%), injection-site erythema (13.7% to 21.4%), and injection-site swelling (11.3% to 13.4%).

 

The most commonly reported solicited adverse reactions in children 2 through 17 years of age vaccinated with a single dose were: injection-site pain (54.8%), myalgia (23.7%), injection-site swelling (20.9%), injection-site erythema (19.2%), fatigue (15.8%), headache (11.9%), and injection-site induration (6.8%).

 

The reported solicited adverse reactions in children 7 through 11 months of age who received 3 doses of VAXNEUVANCE were: fever ≥38.0°C (21.9%), irritability (32.8%), injection-site erythema (28.1%), somnolence (21.9%), injection-site swelling (18.8%), injection-site pain (18.8%), injection-site induration (17.2%), decreased appetite (15.6%), and urticaria (1.6%).

 

The reported solicited adverse reactions in children 12 through 23 months of age who received 2 doses of VAXNEUVANCE were: fever ≥38.0°C (11.3%), irritability (35.5%), injection-site pain (33.9%), somnolence (24.2%), decreased appetite (22.6%), injection-site erythema (21.0%), injection-site swelling (14.5%), and injection-site induration (8.1%).

 

Vaccination with VAXNEUVANCE may not protect all vaccine recipients.

 

Before administering VAXNEUVANCE, please read the accompanying Prescribing Information. The Patient Information also is available.